Trial · NCT03802617
Adverse events128
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
61 to 80 of 128
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Congenital cystic kidney disease | Congenital, familial and genetic disorders | 0.25 μg/kg Group | 0 | 61 | 0 |
| serious | Congenital cystic kidney disease | Congenital, familial and genetic disorders | 0.5 μg/kg Group | 0 | 61 | 0 |
| serious | Congenital cystic kidney disease | Congenital, familial and genetic disorders | 1.0 μg/kg Group | 1 | 62 | 1 |
| serious | Congenital cystic kidney disease | Congenital, familial and genetic disorders | Placebo Group | 0 | 63 | 0 |
| serious | Vitreous opacities | Eye disorders | 0.25 μg/kg Group | 0 | 61 | 0 |
| serious | Vitreous opacities | Eye disorders | 0.5 μg/kg Group | 0 | 61 | 0 |
| serious | Vitreous opacities | Eye disorders | 1.0 μg/kg Group | 1 | 62 | 1 |
| serious | Vitreous opacities | Eye disorders | Placebo Group | 0 | 63 | 0 |
| serious | Large intestine polyp | Gastrointestinal disorders | 0.25 μg/kg Group | 0 | 61 | 0 |
| serious | Large intestine polyp | Gastrointestinal disorders | 0.5 μg/kg Group | 0 | 61 | 0 |
| serious | Large intestine polyp | Gastrointestinal disorders | 1.0 μg/kg Group | 1 | 62 | 1 |
| serious | Large intestine polyp | Gastrointestinal disorders | Placebo Group | 0 | 63 | 0 |
| serious | Small intestinal obstruction | Gastrointestinal disorders | 0.25 μg/kg Group | 0 | 61 | 0 |
| serious | Small intestinal obstruction | Gastrointestinal disorders | 0.5 μg/kg Group | 0 | 61 | 0 |
| serious | Small intestinal obstruction | Gastrointestinal disorders | 1.0 μg/kg Group | 1 | 62 | 1 |
| serious | Small intestinal obstruction | Gastrointestinal disorders | Placebo Group | 0 | 63 | 0 |
| serious | Bacteraemia | Infections and infestations | 0.25 μg/kg Group | 0 | 61 | 0 |
| serious | Bacteraemia | Infections and infestations | 0.5 μg/kg Group | 1 | 61 | 1 |
| serious | Bacteraemia | Infections and infestations | 1.0 μg/kg Group | 0 | 62 | 0 |
| serious | Bacteraemia | Infections and infestations | Placebo Group | 0 | 63 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03802617/events?page=4